With less than three months remaining until the current deadline for the UK to leave the EU, the European Commission has reiterated their message of 21 February 2019, regarding the conditions for marketing authorisation holders to continue batch testing activities in the United Kingdom for a limited period of time after the UK becomes a third country.
In the latest message from the EC, they emphasise the following: "It is essential that marketing authorisation holders use the remaining time to complete their preparations so that by 1 January 2020 all batch testing facilities are fully transferred to the EU27/EEA and the necessary regulatory submissions are completed."
The full message and links to previous communications from the EC can be found in the link below:
https://ec.europa.eu/health/sites/health/files/20190725_news_en.pdf
Regulatory Support for
CMC and GMP
- Management of pharmaceutical & analytical method development
- Technical dossier writing & expert reports
- Data audit & gap analysis
- GMP audits
Find out more about our consultancy and outsourcing options for pharmaceuticals & biologicals.
Cyton Germany is now open for business!
Providing all the services available from Cyton UK, the new office ensures business continuity, post Brexit and beyond, for Cyton and our clients.